Citations

Clear

3138 citation(s) found for "Smith, AM".

TDP‐43 AMPLIFIES MEMORY LOSS AND HIPPOCAMPAL ATROPHY IN ALZHEIMER'S DISEASE
Josephs, Keith A. , Whitwell, Jennifer , Weigand, Stephen D. , Murray, Melissa E. , Tosakulwong, Nirubol , Liesinger, Amanda M., Petrucelli, Leonard , Ivnik, Robert J., Parisi, Joseph E., Petersen, Ronald C. , Senjem, Matthew L. , Knopman, David S. , Boeve, Bradley F. , Smith, Glenn E. , Jack, Clifford R. , Dickson, Dennis W. , Murray, Melissa E

Mayo Clinic

Alzheimer's & Dementia | September 6, 2014 | Volume: 10 | Issue: 4S_Part_16 | Pages: No page available

10.1016/j.jalz.2014.07.149 Get It

O4‐06‐06: APATHY AND REDUCED STRIATAL UPTAKE IN DEMENTIA WITH LEWY BODIES
Graff‐Radford, Jonathan, Lowe, Val J. , Peller, Patrick J., Przybelski, Scott A. , Bennett, Jamie, Aakre, Jeremiah A. , Knopman, David S. , Petersen, Ronald C. , Graff‐Radford, Jonathan , Kantarci, Kejal , Jones, David T. , Ferman, Tanis J. , Smith, Glenn E. , Pankratz, V. Shane , Knopman, David S. , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | September 6, 2014 | Volume: 10 | Issue: 4S_Part_4 | Pages: No page available

10.1016/j.jalz.2014.04.420 Get It

IC‐P‐136: APATHY AND REDUCED STRIATAL UPTAKE IN DEMENTIA WITH LEWY BODIES
Graff‐Radford, Jonathan, Lowe, Val J. , Jones, David, Peller, Patrick J., Przybelski, Scott A. , Bennett, Jamie, Aakre, Jeremiah A. , Petersen, Ronald C. , Graff‐Radford, Jonathan , Kantarci, Kejal , Ferman, Tanis J. , Smith, Glenn E. , Pankratz, V. Shane , Knopman, David S. , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | September 6, 2014 | Volume: 10 | Issue: 4S_Part_7 | Pages: No page available

10.1016/j.jalz.2014.05.142 Get It

Antineoplastic Agents and the Associated Myelosuppressive Effects
Barreto, Jason N. , McCullough, Kristen , Ice, Lauren L., Smith, Judith A. , McCullough, Kristen B, McCullough, Kristen B

Mayo Clinic

Journal of Pharmacy Practice | August 21, 2014 | Volume: 27 | Issue: 5 | Pages: 440-446

10.1177/0897190014546108 | PMID 25147158 Get It

Bone marrow is a complex organ responsible for the regulation of hematopoietic cell distribution throughout the human body. Patients receiving antineoplastic agents as a therapeutic intervention for hematologic malignancy often experience varying degrees of myelotoxicity. Antineoplastic agents cause hypocellularity in marrow resulting in a reduction in hematopoietic tissue activity and a corresponding decline in cell production. Quantifying the adverse effects on hematopoiesis is based on the properties of a single agent, the use of individual drugs within a combination chemotherapy regimen, and the course, or courses, of chemotherapy designed to treat cancer. The direct or indirect suppression of erythrocytes, granulocytes, and megakaryocytes has potential for multiple negative clinical consequences ranging from increased monitoring of blood counts to life-threatening infection and death. This review will provide an overview of the structure and function of competent adult bone marrow, describe the process of hematopoiesis, and characterize the myelotoxicities associated with common antineoplastic agents currently used in the treatment of cancer.
Response to Comments on Zhang et al. Second-Line Agents for Glycemic Control for Type 2 Diabetes: Are Newer Agents Better? Diabetes Care 2014;37:1338–1345
Zhang, Yuanhui , Mason, Jennifer, Smith, Steven A., Shah, Nilay D. , McCoy, Rozalina G. , Denton, Brian T.

Mayo Clinic

Diabetes Care | August 21, 2014 | Volume: 37 | Issue: 9 | Pages: e206-e207

10.2337/dc14-1339 | PMID 25147267 Get It

Review: In diabetes, ACE-Is, but not ARBs, reduce mortality and major CV events compared with placebo or active treatment
Smith, Steven C. , McCoy, Rozalina G.

Mayo Clinic

Annals of Internal Medicine | August 18, 2014 | Volume: 161 | Issue: 4 | Pages: JC2

10.7326/0003-4819-161-4-201408190-02002 | PMID 25133381 Get It

Designing Therapeutic Clinical Trials for Older and Frail Adults With Cancer: U13 Conference Recommendations
Hurria, Arti , Dale, William , Mooney, Margaret , Rowland, Julia H. , Cohen, Harvey Jay, Muss, Hyman B. , Schilsky, Richard L. , Extermann, Martine , Schmader, Kenneth E. , Mohile, Supriya G. , Ballman, Karla V. , FERRELL, BETTY ROLLING

Mayo Clinic

Journal of Clinical Oncology | July 28, 2014 | Volume: 32 | Issue: 24 | Pages: 2587-2594

10.1200/jco.2013.55.0418 | PMID 25071116 Get It

A majority of cancer diagnoses and deaths occur in patients age ≥ 65 years. With the aging of the US population, the number of older adults with cancer will grow. Although the coming wave of older patients with cancer was anticipated in the early 1980s, when the need for more research on the cancer-aging interface was recognized, many knowledge gaps remain when it comes to treating older and/or frailer patients with cancer. Relatively little is known about the best way to balance the risks and benefits of existing cancer therapies in older patients; however, these patients continue to be underrepresented in clinical trials. Furthermore, the available clinical trials often do not include end points pertinent to the older adult population, such as preservation of function, cognition, and independence. As part of its ongoing effort to advance research in the field of geriatric oncology, the Cancer and Aging Research Group held a conference in November 2012 in collaboration with the National Cancer Institute, the National Institute on Aging, and the Alliance for Clinical Trials in Oncology. The goal was to develop recommendations and establish research guidelines for the design and implementation of therapeutic clinical trials for older and/or frail adults. The conference sought to identify knowledge gaps in cancer clinical trials for older adults and propose clinical trial designs to fill these gaps. The ultimate goal of this conference series is to develop research that will lead to evidence-based care for older and/or frail adults with cancer.
Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow‐positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report
Goldman, Stanton, Galardy, Paul J. , Perkins, Sherrie L., Frazer, J. Kimble , Sanger, Warren G., Anderson, James R. , Gross, Thomas G. , Weinstein, Howard J., Harrison, Lauren , Shiramizu, Bruce , Barth, Matthew J. , Cairo, Mitchell S. , Smith, Lynette M.

Mayo Clinic

British Journal of Haematology | July 26, 2014 | Volume: 167 | Issue: 3 | Pages: 394-401

10.1111/bjh.13040 | PMID 25066629 Get It

SummaryChildren and adolescents with Burkitt Lymphoma (BL) and combined central nervous system (CNS) and bone marrow involvement still have a poor prognosis with chemotherapy alone. We therefore investigated in children and adolescents with bone marrow (≥25% blasts) and/or CNS‐positive Burkitt lymphoma the chemoimmunotherapy combination of rituximab (375 mg/m2) and the standard chemotherapy arm of our previously reported French‐American‐British (FAB) Lymphome Malins de Burkitt (LMB) 96 trial. Central pathological and cytogenetic characterization was also performed. There were 40 evaluable patients with Burkitt histology (25 with leukaemia and 15 with CNS disease ± leukaemia). The chemoimmunotherapy regimen was well tolerated. The incidence of grade III/IV mucositis during induction cycles with combined chemotherapy and rituximab was 31% and 26%, respectively. The 3‐year event‐free survival (EFS)/overall survival (OS) was 90% (95% confidence interval [CI], 76–96%) in the entire cohort and 93% (95% CI, 61–99%) in patients with CNS disease. Based on the results of this trial, an international randomized study of FAB/LMB 96 chemotherapy ± rituximab for high‐risk patients is currently under investigation.